NCT04835896View on ClinicalTrials.gov

Study of M7824 and Paclitaxel Combination as a Second-line Treatment in Patients With Recurrent/Metastatic Gastric Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

June 2, 2021

Primary Completion Date

October 27, 2023

Study Completion Date

October 27, 2023

Conditions
Recurrent/Metastatic Gastric Cancer
Interventions
DRUG

M7824+paclitaxel

M7824 will be administered intravenously at a dose of 1200 mg every 3 weeks in combination with paclitaxel 80 (or 70) mg/m2 once a week for 3 weeks (each cycle is 4 weeks)

Trial Locations (1)

Unknown

Yonsei University Health System, Severance Hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER